Asia-Pacific (including Japan) - Strongest growth region supported by rising diabetic population, expanding healthcare access, increasing awareness, and large-scale pharmaceutical manufacturing in China, India, and Southeast Asia, along with Japan's advanced diabetes care ecosystem
Brosseron F, Krauthausen M, Kummer M, Heneka MT
FDA found no adequate clinical program that could define common adverse effects, rare serious effects, dose relationships, medication interactions, or risks in vulnerable patient groups
But - you're probably not going to like the solution...until I tell you my all-time favorite hot tip
Theres no benefit to starting high